Fox Run Management L.L.C. Purchases 19,136 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• Fox Run Management L.L.C. increased its stake in Catalyst Pharmaceuticals by 50.4%, owning a total of 57,118 shares valued at approximately $1,385,000 as of its latest SEC filing.
• Institutional investors now hold 79.22% of Catalyst Pharmaceuticals' stock, with several firms, including Park Square Financial Group and GAMMA Investing, making new purchases or increasing their positions recently.
• Despite recent fluctuations, analysts have a consensus rating of "Buy" for Catalyst Pharmaceuticals, with the average target price set at $33.20.

Fox Run Management L.L.C. boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 50.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,118 shares of the biopharmaceutical company's stock after buying an additional 19,136 shares during the period. Fox Run Management L.L.C.'s holdings in Catalyst Pharmaceuticals were worth $1,385,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter worth $29,000. Sound Income Strategies LLC acquired a new position in Catalyst Pharmaceuticals during the first quarter worth $64,000. GAMMA Investing LLC raised its holdings in Catalyst Pharmaceuticals by 26.2% during the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after buying an additional 579 shares during the last quarter. Quarry LP acquired a new position in Catalyst Pharmaceuticals during the fourth quarter worth $104,000. Finally, New Vernon Capital Holdings II LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter worth $122,000. Institutional investors and hedge funds own 79.22% of the company's stock.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Preethi Sundaram sold 2,324 shares of the firm's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total value of $61,376.84. Following the transaction, the insider owned 42,681 shares in the company, valued at approximately $1,127,205.21. This trade represents a 5.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.40% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CPRX. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Saturday, August 9th. Two investment analysts have rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $33.20.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX traded up $0.24 during trading on Tuesday, hitting $20.47. The stock had a trading volume of 329,841 shares, compared to its average volume of 1,314,838. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.00 and a 12 month high of $26.58. The company has a market capitalization of $2.51 billion, a PE ratio of 12.41, a PEG ratio of 0.82 and a beta of 0.70. The firm has a fifty day moving average of $21.64 and a two-hundred day moving average of $22.67.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.